GlassScriptPhysician profile
Alan Lubin
NPI 1265439442
$179.80
in general payments reported to CMS, 2019-2025
7 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $180.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $58.16 | 2019 | |
| Genzyme Corporation | $50.51 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.47 | 2019 | |
| Amgen INC. | $15.16 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $13.87 | 2019 | |
| Rigel Pharmaceuticals, INC. | $12.76 | 2019 | |
| Seagen INC. | $11.87 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Lubin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.